AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37797632
Drug: Cadonilimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab at 6 mg/kg and a fixed dose of 450 mg every 2 weeks (dose expansion phase)
Trial: 37797632
Drug: Cadonilimab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab at 6 mg/kg every 2 weeks (phase 2)
Trial: 37797733
Drug: Bintrafusp Alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp Alfa (BA) with concurrent chemoradiotherapy (cCRT) followed by BA
Trial: 37797733
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with concurrent chemoradiotherapy (cCRT) followed by durvalumab
Trial: 37798422
Drug: Sulfonylurea treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea treatment for carriers of novel HNF1A variants
Trial: 37798468
Drug: Reparixin 1200
RxNorm normalized name: Réparixine
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparixin 1200 mg three times daily for up to 21 days
Trial: 37798538
Drug: M8891 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M8891 (a selective and reversible inhibitor of methionine aminopeptidase 2)
Trial: 37798650
Drug: HB-adMSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-adMSC therapy (5 intravenous infusions of 2 × 10^6 cells)
Trial: 37798723
Drug: NTHi vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTHi vaccine candidate genes (pd, pe, pilA) and Mcat gene (uspA2)
Trial: 37798723
Drug: NTHi vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTHi vaccine candidate genes (pd, pilA)
Trial: 37798756
Drug: Fascia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia therapy along with conventional physical therapy (hot pack, strengthening, stretching)
Trial: 37798756
Drug: Fascial manipulation
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fascial manipulation treatment with conventional physical therapy
Trial: 37798801
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg for 5 days)
Trial: 37798801
Drug: Colchicine (day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (day 1: 1.5 mg; days 2-5: 1 mg)
Trial: 37798860
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control neurodevelopmental therapy (NDT)
Trial: 38233885
Drug: IVIg (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (2.0 g/kg every 4 weeks for 16 weeks)
Trial: 37799613
Drug: IVIg (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (2.0 g/kg for 6 additional cycles during Extension Period)
Trial: 37799724
Drug: Omicron-adapted vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omicron-adapted vaccine
Trial: 37800112
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with moderate-intensity rosuvastatin (RE 10) and ezetimibe (10 mg)
Trial: 37800374
Drug: Direct transport
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct transport to a comprehensive stroke center (CSC) prioritizing endovascular therapy
Trial: 37800374
Drug: Admission to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission to the nearest primary stroke center (PSC) prioritizing intravenous thrombolysis (IVT)
Trial: 37800415
Drug: High-Dose Trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Trivalent Influenza Vaccine (HD-TIV)
Trial: 37800415
Drug: Standard-Dose Quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Quadrivalent Influenza Vaccine (SD-QIV)
Trial: 37800597
Drug: Nivasorexant 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivasorexant 100 mg administered twice daily (b.i.d.)
Trial: 37800597
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of flurbiprofen (50 mg, CYP2C9), omeprazole (20 mg, CYP2C19), midazolam (2 mg, CYP3A4)
Trial: 37800633
Drug: Long-acting muscarinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting muscarinic antagonist/long-acting β-agonist
Trial: 37800766
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy with osimertinib
Trial: 37801046
Drug: Zanamivir inhalation
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir inhalation
Trial: 37801266
Drug: Zibotentan 5
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 5 mg (single oral dose)
Trial: 37801315
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) and radiation therapy (RT) plus docetaxel
Trial: 37801358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (existing oral care routines)
Trial: 37801454
Drug: Dietary modification
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary modification as part of lipid-lowering therapy
Trial: 37801658
Drug: Intermittently Scanned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections
Trial: 37801674
Drug: HER3-DXd 1.6-8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER3-DXd 1.6-8.0 mg/kg intravenously once every 3 weeks
Trial: 37801707
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (rituximab + chlorambucil)
Trial: 37801789
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral iron supplementation (FeSO4)
Trial: 37802038
Drug: Single-dose intrahippocampal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intrahippocampal delivery of cryopreserved, post-mitotic, medial ganglionic eminence (MGE) pallial-type GABAergic interneurons.
Trial: 37802566
Drug: PGT121 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121 + VRC07-523LS (treatment one; n=6)
Trial: 37802566
Drug: PGDM1400 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGDM1400 + VRC07-523LS (treatment two; n=6)
Trial: 37802566
Drug: 10-1074 +
RxNorm normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-1074 + VRC07-523LS (treatment three; n=6)
Trial: 37802566
Drug: PGDM1400 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGDM1400 + PGT121 + VRC07-523LS (treatment four; n=9)
Trial: 37802608
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (SCRT) combined with chemotherapy and PD-1 inhibitor (toripalimab)
Trial: 37802619
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation therapies (OATs)
Trial: 37802679
Drug: Chlormethine (CL)
RxNorm normalized name: chlormethine
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlormethine (CL) gel
Trial: 37803096
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy prior to robot-assisted therapy
Trial: 37803096
Drug: Sham mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham mirror therapy prior to robot-assisted therapy
Trial: 37803368
Drug: Beclometasone dipropionate/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/G) 100/6/10 µg, two inhalations twice-daily for 6 weeks after switching from high-dose ICS/LABA.
Trial: 37803368
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled corticosteroid/long-acting β-agonist (ICS/LABA) regimen prior to switching.
Trial: 37803467
Drug: Compassion and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassion and Mindfulness Intervention for RA (MITIG.RA) + Treatment as Usual (TAU)
Trial: 37803473
Drug: Expression level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expression level of placental omega-3 receptors
Trial: 37803759
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet (≥20 g/d DF)
Trial: 37804162
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training using cuff weights/dumbbells at light intensity (40%-50% of maximum one repetition, 10-15 repetitions for one to three times a day) for major muscle groups of upper and lower limbs on a weekly basis.
Trial: 37804162
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy group (control group).
Trial: 37804307
Drug: Aortix therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortix therapy
Trial: 37804430
Drug: Palovarotene 20
RxNorm normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 20 mg (whole capsule or sprinkled on food)
Trial: 37804430
Drug: Palovarotene 20
RxNorm normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 20 mg
Trial: 37804674
Drug: Dalfampridine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine (10 mg twice daily) plus physiotherapy (twice a week)
Trial: 37804765
Drug: B cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell depletion therapy
Trial: 37805605
Drug: Thyme honey
RxNorm normalized name: THYME
DrugBank: Thyme (DB10983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyme honey oral rinse
Trial: 37806074
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction chemotherapy (SIC)
Trial: 37806075
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1000 mg/day)
Trial: 37806314
Drug: HU6 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU6 150 mg
Trial: 37806314
Drug: HU6 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU6 300 mg
Trial: 37806314
Drug: HU6 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HU6 450 mg
Trial: 37806333
Drug: Drug-eluting balloon
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting balloon (DEB) in the side branch
Trial: 37806333
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent (DES) in the side branch
Trial: 37806651
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg extended-release daily
Trial: 37807179
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g TXA bolus
Trial: 37807179
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g bolus + 1 g/8 hours TXA infusion
Trial: 37811634
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg once daily with limertinib 160 mg (Part A)
Trial: 37811634
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg twice daily with limertinib 80 mg (Part B)
Trial: 37811993
Drug: Ad26 mosaic
RxNorm normalized name: Ad26.Zebov
DrugBank: VAC-52150 (DB17781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26 mosaic vaccine regimen
Trial: 37812229
Drug: Analgesic administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic administration
Trial: 37812272
Drug: Trauma Focused
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Focused Cognitive Behavioral Therapy (TF-CBT)
Trial: 37812307
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (BSS) supplementation before intraocular lens (IOL) implantation and before the end of surgery.
Trial: 37812381
Drug: Prophylactic norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine 0 µg/kg/min
Trial: 37812381
Drug: Prophylactic norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine 0.025 µg/kg/min
Trial: 37812381
Drug: Prophylactic norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine 0.05 µg/kg/min
Trial: 37812381
Drug: Prophylactic norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine 0.075 µg/kg/min
Trial: 37812381
Drug: Prophylactic norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine 0.1 µg/kg/min
Trial: 37812429
Drug: XEN1101 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 25 mg
Trial: 37812429
Drug: XEN1101 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 20 mg
Trial: 37812429
Drug: XEN1101 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 10 mg
Trial: 37812679
Drug: Darolutamide 600
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide 600 mg plus ADT and docetaxel
Trial: 37813304
Drug: Continuous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous oxytocin infusion (16 hours, with a 4 hours pause in between infusions)
Trial: 37813418
Drug: Early antihypertensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antihypertensive treatment started within 24-48 hours aimed at reducing systolic blood pressure by 10%-20% within the first 24 hours and achieving mean blood pressure <140/90 mm Hg within seven days.
Trial: 37813418
Drug: Delayed antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antihypertensive treatment starting on day 8 aimed at achieving mean blood pressure <140/90 mm Hg.
Trial: 37813959
Drug: Dinutuximab beta
RxNorm normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dinutuximab beta (continuous infusion over 10 days of each cycle, for up to five cycles)
Trial: 37814129
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg escitalopram (n=17)
Trial: 37814541
Drug: Olme/Amlo/Rosu 20/5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olme/Amlo/Rosu 20/5/5 mg
Trial: 37814541
Drug: Olme/Amlo/Rosu 20/5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olme/Amlo/Rosu 20/5/10 mg
Trial: 37814541
Drug: Amlo/Olme 20/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlo/Olme 20/5 mg
Trial: 37814892
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP target 130 to <150 mm Hg)
Trial: 37815096
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy for 24 weeks
Trial: 37815094
Drug: Tighter glycaemic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tighter glycaemic control (≤ 5.0 to 5.1 mmol/L fasting plasma glucose; ≤ 6.7 to 7.4 mmol/L postprandial)
Trial: 37815254
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion (1.5 µg/min) for 20 minutes
Trial: 37815398
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg telavancin
Trial: 37815489
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plasma microbial cell-free DNA sequencing and usual care testing
Trial: 37815790
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use in NICU
Trial: 37815957
Drug: Prophylactic psychopharmacological
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic psychopharmacological treatment (mainly first-generation antipsychotics)
Trial: 37816198
Drug: PROStep intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PROStep intervention with weekly text message-based symptom surveys and passive activity monitoring using a wearable accelerometer; additional text-based active choice prompt in one arm
Trial: 37816249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of K MAX and A F
Trial: 37816249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of K MAX and P MIN
Trial: 37816249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of K 2F and R mB
Trial: 37816489
Drug: Silane-Adhesive treatment
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silane-Adhesive treatment (application of a silane coupling agent after acid etching)
Trial: 37816489
Drug: Sandblast-Silane-Adhesive treatment
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblast-Silane-Adhesive treatment (intra-oral sandblasting followed by silane application)
Trial: 37816489
Drug: Control (No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (No additional treatment)
Trial: 37816552
Drug: Multimodal prehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal prehabilitation combined with ERAS, at least 2 weeks before gastrectomy, including physical and respiratory training, nutritional support, and therapy and psychosocial treatment
Trial: 37816552
Drug: ERAS pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERAS pathway treatment
Trial: 37816561
Drug: Weekly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text messaging encouraging exclusive breastfeeding plus in-person individual motivational interviews at weeks 2, 6, and 10.
Trial: 37816943
Drug: Sequential arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential arm
Trial: 37817124
Drug: Bilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sequential TBS (continuous TBS to the right and intermittent TBS to the left DLPFC)
Trial: 37817124
Drug: Bilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sequential TBS
Trial: 37817147
Drug: Day patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day patient treatment (DP) after short inpatient (IP) stabilization
Trial: 37817147
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (IP) as usual
Trial: 37817255
Drug: Doxapram therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram therapy
Trial: 37817267
Drug: Behavioral sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral sleep extension intervention (sleep coaching) for 8 weeks followed by monthly coaching for 2 months
Trial: 37817267
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education (control) for 8 weeks followed by monthly education for 2 months
Trial: 37817565
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation (CRT) regimen consisting of 2 cycles of chemotherapy with DCF (docetaxel, cisplatin, and 5-fluorouracil) followed by preoperative CRT with oxaliplatin, continuous 5FU and radiotherapy (45 Gy in 25 fractions of 1.8 Gy, 5 fractions per week for 5 weeks)
Trial: 37818279
Drug: Guideline-adherent treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-adherent treatments (exercise, education, dietary weight management)
Trial: 37818279
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment pathways